RxDoctor Payments Data

Jodie Barr, DO

Hematology & Oncology · Lawrence, KSNPI 1588891451

Payments from drug & device makers

What this record shows

6 manufacturers reported payments, led by Seagen Inc. at 46.1% of the total. 2025 is the largest year on record at $170, 2.0 times the $84 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in KS, where the typical reported total is $1,410.

$434in general payments, 2019–2025

Across 14 payments — averaging $30.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$200
  • Merck$113
  • Sanofi$69
  • Puma Biotechnology, Inc.$29
  • Novartis$16
  • Pfizer$7
$10,000in research payments, 2019–2025

Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$10K

What the payments were for

  • Food & beverage$20447%
  • Education$23053%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Seagen Inc.2$200
Merck6$113
Sanofi1$69
Puma Biotechnology, Inc.2$29
Novartis1$16
Pfizer2$7

How this compares

$434 in reported general payments places this provider in the 25th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$130,940
Medicare patients
410
Services billed
1,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib31$563,727
Lenalidomide27$436,509
RevlimidLenalidomide23$357,947
JakafiRuxolitinib Phosphate22$349,312
CalquenceAcalabrutinib Maleate14$107,788
KisqaliRibociclib Succinate14$91,701
CreonLipase/Protease/Amylase16$32,808
EliquisApixaban25$29,210
Anastrozole239$2,840
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$944
Tamoxifen Citrate63$824
Oxycodone Hcl22$772
Letrozole55$740
Dexamethasone42$624
Hydroxyurea41$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$7$592,93856 claims
NovartisKisqali$16$91,70114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 97 hematology & oncology providers in Kansas.

Other hematology & oncology in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →